<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091908</url>
  </required_header>
  <id_info>
    <org_study_id>V87_25</org_study_id>
    <nct_id>NCT02091908</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions</brief_title>
  <official_title>Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18
      through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying
      medical conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving seroconversion</measure>
    <time_frame>day 43</time_frame>
    <description>Seroconversion is defined as hemagglutination inhibition (HI) ≥1:40 for subjects who were seronegative at baseline [day 1 HI titer &lt;1:10] or a minimum 4-fold increase in HI titer for subjects who were seropositive at baseline [day 1 HI titer ≥1:10])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratios (GMRs) as determined by HI assay</measure>
    <time_frame>day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with an HI titer ≥1:40</measure>
    <time_frame>day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited and unsolicited adverse events</measure>
    <time_frame>day 202</time_frame>
    <description>In pooled age groups 18 years of age and older subjects who are healthy or with underlying medical condition who have received aTIV or aH5N1 vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) as determined by HI</measure>
    <time_frame>day 1</time_frame>
    <description>HI assay: homologous antibody responses to aH5N1 vaccine 3 weeks after first vaccination (day 22) according to CHMP immunogenicity criteria in adult and elderly subjects who are healthy or with underlying medical condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratios (GMRs) as determined by SRH</measure>
    <time_frame>day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an HI titer ≥1:40</measure>
    <time_frame>day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion</measure>
    <time_frame>day 22</time_frame>
    <description>Seroconversion is defined as SRH area ≥25 mm2 for subjects who were seronegative at baseline [day 1 SRH area ≤3.997 mm2] or a significant increase [at least 50% increase] in SRH area for subjects who were seropositive at baseline [SRH area &gt;3.997 mm2])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with geometric mean area ≥25 mm2</measure>
    <time_frame>day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion</measure>
    <time_frame>day 22</time_frame>
    <description>Seroconversion is defined as HI ≥1:40 for subjects who were seronegative at baseline [day 1 HI titer &lt;1:10] or a minimum 4-fold increase in HI titer for subjects who were seropositive at baseline [day 1 HI titer ≥1:10])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs as determined by SRH</measure>
    <time_frame>day 43 (3 weeks after the second vaccination)</time_frame>
    <description>Serial radial haemolysis (SRH) assay: homologous antibody responses to aH5N1 vaccine 3 weeks after first and second vaccinations (day 22 and day 43) according to CHMP immunogenicity criteria in adult and elderly subjects who are healthy or with underlying medical condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMRs as determined by HI</measure>
    <time_frame>day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) as determined by HI</measure>
    <time_frame>day 43 (3 weeks after the second vaccination)</time_frame>
    <description>HI assay: homologous antibody responses to aH5N1 vaccine 3 weeks after first vaccination (day 22) according to CHMP immunogenicity criteria in adult and elderly subjects who are healthy or with underlying medical condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) as determined by HI</measure>
    <time_frame>day 22 (3 weeks after the first vaccination)</time_frame>
    <description>HI assay: homologous antibody responses to aH5N1 vaccine 3 weeks after first vaccination (day 22) according to CHMP immunogenicity criteria in adult and elderly subjects who are healthy or with underlying medical condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMRs as determined by SRH</measure>
    <time_frame>day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with an HI titer ≥1:40</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with geometric mean area ≥25 mm2</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with geometric mean area ≥25 mm2</measure>
    <time_frame>day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion</measure>
    <time_frame>day 43</time_frame>
    <description>Seroconversion is defined as SRH area ≥25 mm2 for subjects who were seronegative at baseline [day 1 SRH area ≤3.997 mm2] or a significant increase [at least 50% increase] in SRH area for subjects who were seropositive at baseline [SRH area &gt;3.997 mm2])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs as determined by SRH</measure>
    <time_frame>day 1</time_frame>
    <description>Serial radial haemolysis (SRH) assay: homologous antibody responses to aH5N1 vaccine 3 weeks after first and second vaccinations (day 22 and day 43) according to CHMP immunogenicity criteria in adult and elderly subjects who are healthy or with underlying medical condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratios (GMRs) as determined by SRH</measure>
    <time_frame>day 43 (3 weeks after the second vaccination)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Arm 1: aH5N1 adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aH5N1 healthy and non-healthy adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: aH5N1 elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aH5N1 healthy and non-healthy elderly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: aTIV adult</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aTIV healthy and non-healthy adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: aTIV elderly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aTIV healthy and non-healthy elderly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Investigational H5N1 vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 1: aH5N1 adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Investigational H5N1 vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 2: aH5N1 elderly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Seasonal Influenza Vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 3: aTIV adult</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Seasonal Influenza Vaccine</intervention_name>
    <description>2 doses of 0.5 ml, 3 weeks apart</description>
    <arm_group_label>Arm 4: aTIV elderly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Male and female individuals 18 years of age and older at the time of enrollment who
             are mentally competent, willing and able to understand the nature and risks of the
             proposed study, and able to sign the consent form prior to study entry;

          -  Individuals who are able to comply with all study procedures and requirements;

          -  Healthy volunteers and volunteers specifically with underlying COPD, cardiovascular
             disease, diabetes mellitus, peripheral vascular disease, or renal impairment may be
             eligible;

          -  Please contact the site for additional eligibility criteria.

        Exclusion Criteria:

          -  Individuals who are not able to follow all the required study procedures for the whole
             period of the study;

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the Investigator, may interfere with the subject's ability to
             participate in the study;

          -  Please contact the site for additional eligibility criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>001, Novartis Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>003, Novartis Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>005, Novartis Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>006, Novartis Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>004, Novartis Investigational Site</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>002, Novartis Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.</citation>
    <PMID>17029131</PMID>
  </reference>
  <reference>
    <citation>Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/5f2ae0fb-53f1-48c2-aa19-9114765ba029. Capecchi, Pamela [corrected to Capecchi, Pier Leopoldo].</citation>
    <PMID>19197383</PMID>
  </reference>
  <reference>
    <citation>Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001 Mar 21;19(17-19):2673-80.</citation>
    <PMID>11257408</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>H5N1</keyword>
  <keyword>aH5N1</keyword>
  <keyword>H5N1 vaccine</keyword>
  <keyword>Pandemic Influenza vaccine</keyword>
  <keyword>MF59, Adjuvant, Avian flu</keyword>
  <keyword>Underlying medical conditions</keyword>
  <keyword>Underlying cardiovascular medical condition</keyword>
  <keyword>Pandemic vaccine</keyword>
  <keyword>Charlson Comorbidity Index (CCI)</keyword>
  <keyword>Adjuvanted vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

